FOR IMMEDIATE RELEASE

Pulmatrix to Present New Data at American Thoracic Society (ATS)

Cambridge, MA, May 19, 2010 - Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the treatment and prevention of infectious and progressive respiratory diseases, today announced it will be presenting new data at the American Thoracic Society (ATS) Annual Meeting, being held May 14-19 in New Orleans, Louisiana.

The results of these studies suggest that Pulmatrix's inhaled cationic airway lining modulator (iCALM) therapies represent a novel therapeutic approach for influenza that may provide a therapeutic benefit to primary infections as well as beneficially impact infection control.

The schedule of the data presentation is as follows:

Abstract Title: Inhaled cationic airway lining modulator (iCALM) therapy, a novel aerosol treatment for respiratory infections reduces clinical symptoms and transmission of Influenza A infection.
Poster Board: 625
Abstract Number: 11519
Session Info: Poster Discussion Session- Poster Presentation, [D25] COMMUNITY ACQUIRED PNEUMONIA: CONTROVERSIES IN MANAGEMENT
Day/Date: Wednesday, May 19, 2010
Session Time: 8:15 AM - 10:45 AM
Location: Room 293-294 (Second Level), Morial Convention Center

Abstracts and information about the ATS and its Annual Meeting may be found at www.thoracic.org

"We anticipate these new data will further illustrate the powerful potential of our therapeutic approach in the treatment of progressive and infectious respiratory disease," said Robert Connelly, CEO of Pulmatrix. "We look forward to sharing these new findings with the scientific and business communities convening at ATS."

About Pulmatrix
Pulmatrix is discovering and developing a new class of host targeted therapies that treat and prevent a broad range of infectious and progressive respiratory diseases by harnessing the airway and lungs own natural biophysical properties and host defense mechanisms. Pulmatrix's innovative technology is pathogen-independent so it has broad potential to treat a wide range of respiratory diseases, including respiratory infections such as influenza; ventilator acquired pneumonia (VAP) and respiratory syncytial virus (RSV), as well as progressive respiratory diseases such as COPD, asthma, and cystic fibrosis. The Pulmatrix technology is based on the ground-breaking scientific work of renowned Harvard Professor David Edwards and Pulmatrix scientists, and is financed by leading life science investors Polaris Venture Partners, 5AM Ventures, ARCH Venture Partners, and the Novartis Bioventures Fund. For additional information about the Company, please visit http://www.pulmatrix.com.

# # #